Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07267949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Acesion Pharma (from the registry)
Registry
  • NCT NCT07267949
  • EU CT 2025-521377-14-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Bulgaria, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Serbia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07267949. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-22 (actual); primary completion 2027-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
Acronym
END-AF-1
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
AP31969
Intervention (Drug)
Placebo
Lead sponsor
Acesion Pharma (class: industry)

Record details

Record id
cardio:ct-nct07267949
Content hash
28745d99e5aacd26bfba7afc8cc3f759cfe4c09ce7925a54435bc16276273773